Review: Estrogen improves symptoms of overactive bladder in postmenopausal women

March 2005
ACP Journal Club;Mar/Apr2005, Vol. 142 Issue 2, p48
Academic Journal
The article cites a study which reviews the effects of estrogens for symptoms suggestive of overactive bladder. The study was published in the 2004 issue of the journal "Acta Obstetrica et Gynecologia Scandinavica." Patients who received estrogen therapy had greater improvement in diurnal frequency, nocturnal frequency, urgency, incontinence episodes, first sensation to void, and bladder capacity than those who received placebo. Estrogen therapies administered locally improve all outcomes. Systemically administered estrogens improve incontinence episodes and first sensation to void, but worsen nocturnal frequency.


Related Articles

  • Interleukin-16 is not Involved in the Pathogenesis of Endometriosis. Xinmei Zhang // Fertility Weekly;5/9/2005, p3 

    This article cites a study conducted by X. Zhang and colleagues which was published in a 2005 issue of the journal "Acta Obstetricia et Gynecologica Scandinavica." It is reported that interleukin (IL)-16 does not play a part in the pathogenesis of pelvic endometriosis. Included in the study were...

  • Zero Percent 24-h Sperm Motility Indicates Occult Infertility.  // Fertility Weekly;6/24/2002, p13 

    This article reports that zero percent 24-h sperm motility is associated with reduced fertilization, and may indicate hidden male infertility. A study was conducted to examine the relationship of 24-hr sperm motility between post insemination and fertilization in vitro in a population with no...

  • Review: oestrogen improves symptoms of overactive bladder in postmenopausal women. Thacker, Holly L. // Evidence Based Medicine;Apr2005, Vol. 10 Issue 2, p50 

    The article presents a medical study, which discusses whether in postmenopausal women with symptoms suggestive of overactive bladder (OAB) (urge or stress incontinence), oestrogen therapy reduces symptoms more than placebo. In postmenopausal women with symptoms suggestive of overactive bladder...

  • Plasma Homocysteine in Women Taking Hormone Replacement Therapy: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Barnabei, Vanessa M.; Phillips, Terry M.; Hsia, Judith // Journal of Women's Health & Gender-Based Medicine;Nov99, Vol. 8 Issue 9, p1167 

    Elevated plasma homocysteine levels have been associated with increased atherosclerotic disease risk. Estrogen and estrogen/progestin replacement therapy have been suggested to lower plasma homocysteine levels in postmenopausal women. To assess the impact of hormone replacement therapy (HRT) on...

  • High-dose gabapentin = estrogen for hot flashes.  // Journal of Family Practice;Oct2006, Vol. 55 Issue 10, p846 

    The article presents a study on the effectiveness of high-dose gabapentin as usual-dose estrogen for the treatment of postmenopausal hot flashes. Menopausal women aged 35 to 60 years with at least 50 moderate hot flashes weekly for at least two months were recruited. The women were randomized to...

  • Symptom Experience After Discontinuing Use of Estrogen Plus Progestin. Ockene, Judith K.; Barad, David H.; Cochrane, Barbara B.; Larson, Joseph C.; Gass, Margery; Wassertheil-Smoller, Sylvia; Manson, JoAnn E.; Barnabei, Vanessa M.; Lane, Dorothy S.; Brzyski, Robert G.; Rosal, Milagros C.; Wylie-Rosett, Judy; Hays, Jennifer // JAMA: Journal of the American Medical Association;7/13/2005, Vol. 294 Issue 2, p183 

    Context Little is known about women’s experiences after stopping menopausal hormone therapy. Objective To describe women’s symptoms and management strategies after stopping the intervention in a large estrogen plus progestin trial. Design, Setting, and Participants Cross-sectional...

  • Estrogen Prevents 5-HT1A Receptor-Induced Disruptions of Prepulse Inhibition in Healthy Women. Gogos, Andrea; Nathan, Pradeep J.; Guille, Valérie; Croft, Rodney J.; van den Buuse, Maarten // Neuropsychopharmacology;Apr2006, Vol. 31 Issue 4, p885 

    The sex steroid hormone, estrogen, has been proposed to be protective against schizophrenia. This study examined the effects of estrogen treatment on modulation of prepulse inhibition (PPI) by the serotonin-1A (5-HT1A) receptor partial agonist, buspirone. PPI is a model of sensorimotor gating,...

  • Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Lindsay, Robert; Gallagher, Christopher J.; Kleerekoper, Michael; Pickar, James H. // Osteoporosis International;Apr2005, Vol. 16 Issue 4, p372 

    Lower doses of conjugated estrogens (CE) alone or combined with lower doses of medroxyprogesterone acetate (MPA) increase mean bone mineral density (BMD) from baseline at the spine and hip in early postmenopausal women. However, not all women on therapy gain BMD. The incidence of continued bone...

  • Conjugated estrogens poses questions in breast cancer risk.  // Reactions Weekly;5/6/2006, Issue 1100, p4 

    Discusses the results of a study regarding conjugated equine estrogen (CEE) use in postmenopausal women with prior hysterectomy. Comparison of the reduction rate in the annual incidences of invasive breast cancer and total breast cancer in women who received CEE with placebo recipients;...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics